A
Antonio Craxì
Researcher at University of Palermo
Publications - 699
Citations - 44773
Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Hepatic Hepatitis C Virus RNA in Chronic Hepatitis C
TL;DR: The sustained biochemical response to interferon appears to be long-lasting even when the virus continues to replicate, and the chances of losing HCV RNA are especially low for patients with cirrhosis.
Journal ArticleDOI
Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort.
Piero Luigi Almasio,Anna Licata,Marcello Maida,Fabio Salvatore Macaluso,Andrea Costantino,N. Alessi,Stefania Grimaudo,Giulia Accardi,Calogero Caruso,Antonio Craxì +9 more
TL;DR: At onset, higher biochemical activity was observed in younger patients, whereas rs12979860 CC genotype was associated with milder histological stage, and HLA-DRB1*08 alleles increase susceptibility to disease development.
Journal ArticleDOI
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
Antonio Craxì,S. Koutsounas,P. Ogurtsov,Liliana Chemello,Mojca Matičič,J. Torras,Moisés Diago,M. T. Tartaglione,T. Witthoeft,X. Yu,R. Faruqi,E. Chaudhri,Lisa D. Pedicone,Eli Zuckerman +13 more
TL;DR: It is demonstrated that peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks is an effective treatment strategy for treatment‐naive patients with G1 CHC and low viral load who attain RVR.
Journal ArticleDOI
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
A. Cespiati,Salvatore Petta,Rosa Lombardi,Vito Di Marco,Vincenza Calvaruso,Cristina Bertelli,Giuseppina Pisano,Erika Fatta,G. Sigon,F. Iuculano,Luciano Crapanzano,Gerlando Gibilaro,Paolo Francione,Antonio Craxì,Silvia Fargion,Anna Ludovica Fracanzani +15 more
TL;DR: AIM to evaluate in patients with CHC whether hepatic steatosis diagnosed by CAP modifies after DAAs-induced sustained virologic response (SVR), and de novo Steatosis and resolution of baseline ste atosis are closely related to the presence of metabolic comorbidities.